Arm Holdings' first quarter as a publicly listed company began with a 22% top-line print and ended with the stock down more than a third from its June high. Revenue ran ahead of the year-ago quarter by $236M - $106M more in license fees, $130M more in royalties. Operating costs grew faster than revenue, the operating-income line slipped from $114M to $91M, and net income nearly doubled to $270M (from $130M) only because $128M of the print came from fair-value gains on equity investments rather than the operating business. The harder read is the chart: after a five-fold run from $100.02 in early February to $452.70 on June 18, the stock gave back roughly $174 per share - about 38% - through the Q1 results and the seven weeks that followed, closing at $278.65 on August 13. The market is no longer rewarding the operating print alone. It is asking whether the cost structure, the customer concentration with the controlling shareholder, and the still-untested Arm AGI CPU pivot can carry a stock trading near 57x EV/Sales and 285x trailing GAAP earnings.
The accounting on the cost side frames the bear case. Research and development grew 29% year over year to $838M; selling, general and administrative grew 22% to $317M; pre-tax share-based compensation grew 42% to $343M, of which $247M sat inside R&D. Combined operating expenses grew $253M while revenue grew $236M - the entire revenue lift was absorbed by opex, plus $6M more in cost of sales. Operating-income margin compressed from 10.8% to 7.1%. The reported net-income beat is real but cosmetic: of the $140M improvement in pre-tax income, $124M came from "Income (loss) from equity investments, net," a line driven by fair-value marks on Arm's stakes in publicly-listed companies and a SoftBank-affiliated equity-method investment, not by royalty checks from licensees.
The bull case lives in two facts the bear case has to absorb. Royalty revenue grew 22% to $715M, with management attributing the lift to "an improved mix of products with higher royalty rates per chip, such as Armv9 and Arm CSS technology, and increased deployment of Arm-based chips in data centers." Armv9 is the per-chip royalty uplift the entire investment case has rested on since the 2023 IPO, and the data-center royalty line is the part of the story the market believes is set to compound as hyperscalers standardize on Arm-based CPUs. Operating cash flow of $902M - a $570M year-over-year increase - was the second-strongest print Arm has reported as a public company, supported by working-capital tailwinds that may not repeat. And the net-cash balance sheet - with $3,058M in cash and equivalents plus $830M in short-term investments against no debt - gives the company years of runway to keep funding the cost build before the AGI CPU has to pay for itself.
The investment case the market is now pricing is whether the operating-leverage curve flattens, softens, or re-accelerates from here. Q1 is the first quarter of FY2027, and the operating cost run-rate just lifted again. The next three quarters - through fiscal year-end March 31, 2027 - show whether R&D growth of 29% and SBC growth of 42% are the new floor or a temporary over-build. The five numbers that decide the rest of the year are written out at the end of this report.